CoChat

Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity

Open access
Wright, Gabriela, Golubeva, Volha, Remsing Rix, Lily L., Berndt, Norbert, Luo, Yunting, Ward, Grace A., Gray, Jhanelle E., Schonbrunn, Ernst, Lawrence, Harshani R., Monteiro, Alvaro N.A., Rix, Uwe · 2017 · ACS Chemical Biology

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

Inhibition of the WEE1 tyrosine kinase enhances anticancer chemotherapy efficacy. Accordingly, the WEE1 inhibitor AZD1775 (previously MK-1775) is currently under evaluation in clinical trials for cancer in combination with chemotherapy. AZD1775 has been reported to display high selectivity and is therefore used in many studies as a probe to interrogate WEE1 biology. However, AZD1775 also exhibits anticancer activity as a single agent although the underlying mechanism is not fully understood. Using a chemical proteomics approach, we here describe a proteome-wide survey of AZD1775 targets in lung cancer cells and identify several previously unknown targets in addition to WEE1. In particular, we observed polo-like kinase 1 (PLK1) as a new target of AZD1775. Importantly, in vitro kinase assays showed PLK1 and WEE1 to be inhibited by AZD1775 with similar potency. Subsequent loss-of-function experiments using RNAi for WEE1 and PLK1 suggested that targeting PLK1 enhances the pro-apoptotic and antiproliferative effects observed with WEE1 knockdown. Combination of RNAi with AZD1775 treatment suggested WEE1 and PLK1 to be the most relevant targets for mediating AZD1775's anticancer effects. Furthermore, disruption of WEE1 by CRISPR-Cas9 sensitized H322 lung cancer cells to AZD1775 to a similar extent as the potent PLK1 inhibitor BI-2536 suggesting a complex crosstalk between PLK1 and WEE1. In summary, we show that AZD1775 is a potent dual WEE1 and PLK1 inhibitor, which limits its use as a specific molecular probe for WEE1. However, PLK1 inhibition makes important contributions to the single agent mechanism of action of AZD1775 and enhances its anticancer effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acschembio.7b00147

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Research works printed but not linked: 1

  1. 10.1158/1535-7163.MCT-15-0692-T · doi:10.1158/1535-7163.mct-15-0692-t

Cited by

See all 81

Metadata

Authors
Wright, G., Golubeva, V., Remsing Rix, L. L., Berndt, N., Luo, Y., Ward, G. A., Gray, J. E., Schonbrunn, E., Lawrence, H. R., Monteiro, A. N. A., & Rix, U.
Affiliations
  • Moffitt Cancer Center (US)
  • Drug Discovery Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States
  • University of South Florida (US)
  • Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States
Corresponding author
Rix, Uwe
Venue
ACS Chemical Biology
Published
2017-06-07
Volume
12
Issue
7
Pages
1883-1892
ISSN
  • 1554-8929 (ISSN-L)
  • 1554-8937
OpenAlex
W2619325549
Cited by
77
References
44
Citations by year
2026: 8 · 2025: 8 · 2024: 4 · 2023: 15 · 2022: 10 · 2021: 9 · 2020: 7 · 2019: 8 · 2018: 4 · 2017: 4
FWCI
3.50
Type
journal article
Language
en
Open access
Locations
  • ACS Chemical Biology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute (R01 CA181746)
  • H. Lee Moffitt Cancer Center and Research Institute
  • Moffitt Cancer Center
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords
AZD1775, WEE1, PLK1, dual kinase inhibition, lung cancer, chemoproteomics, CRISPR/Cas9, BI2536, apoptosis, antiproliferative activity
MeSH terms
Polo-Like Kinase 1, Antineoplastic Agents, Cell Survival, Dose-Response Relationship, Drug, Enzyme Activation, Humans, Lung Neoplasms, Nuclear Proteins, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Pyrazoles, Pyrimidines, Pyrimidinones, Immunoblotting, Molecular Structure, Drug Delivery Systems, Apoptosis, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Cell Line, Tumor, Cell Proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.